foxo4 dri human trials results FOXO4-DRI PEPTIDE 2MG/5MG/10MG VIAL – UMBRELLA Labs 2022 Lupus Highlight - Therapeutic
2022 Lupus Highlight Therapeutic Targeting of Senescent Cells in Lupus, Lupus Research Program, Congressionally Directed Medical Research Programs Peptide inhibitors targeting FOXO4 p53 interactions and inducing senescent cancer cell specific apoptosis bioRxiv CHK2 USP37 axis stabilizes FOXO4 to sustain senescence and evade apoptosis PNAS FOXO4 DRI Peptide Dosing Guide: Senolytic Peptide Protocol (June 2026) FOXO4 DRI alleviates age related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice Aging
Pay in 4 interest-free payments of $5.50 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 5 - Aug 10



